Eton Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Eton Pharmaceuticals, Inc. (ETON) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 7.78 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 7.09M shares, a 44.75% increase year-over-year.
- Eton Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 7.43M shares, a 11.89% increase year-over-year.
- Eton Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 4.13M shares, a 30.49% decline year-over-year.
- Eton Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 4.90M shares, a 12.86% decline year-over-year.
- Eton Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 7.78M shares, a 21.78% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 6.39M shares, a 17.92% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 5.42M shares, a 1.38% decline from fiscal 2022.
- Eton Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 5.49M shares, a 28.17% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 8 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 7.78M shares 10-K · filed 2026-03-19 | |||||||
| 2025-09-30 | 7.09M shares 10-Q · filed 2025-11-06 | 7.63M shares 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | 7.43M shares 10-Q · filed 2026-08-13 | 7.18M shares 10-Q · filed 2026-08-13 | ||||||
| 2025-03-31 | 4.13M shares 10-Q · filed 2026-05-14 | |||||||
| 2024-12-31 | 6.39M shares 10-K · filed 2026-03-19 | |||||||
| 2024-09-30 | 4.90M shares 10-Q · filed 2025-11-06 | 6.32M shares 10-Q · filed 2025-11-06 | ||||||
| 2024-06-30 | 6.64M shares 10-Q · filed 2025-08-07 | 6.28M shares 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | 5.94M shares 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | 5.42M shares 10-K · filed 2026-03-19 | |||||||
| 2023-09-30 | 5.62M shares 10-Q · filed 2024-11-12 | 4.82M shares 10-Q · filed 2024-11-12 | ||||||
| 2023-06-30 | 4.89M shares 10-Q · filed 2024-08-08 | 4.89M shares 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 5.44M shares 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | 5.49M shares 10-K · filed 2025-03-18 | |||||||
| 2022-09-30 | 5.35M shares 10-Q · filed 2023-11-09 | 5.12M shares 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | 5.56M shares 10-Q · filed 2023-08-10 | 5.34M shares 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | 5.11M shares 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | 4.29M shares 10-K · filed 2024-03-14 | |||||||
| 2021-09-30 | 4.34M shares 10-Q · filed 2022-11-10 | 4.28M shares 10-Q · filed 2022-11-10 | ||||||
| 2021-06-30 | 4.27M shares 10-Q · filed 2022-08-11 | 4.27B shares 10-Q · filed 2021-08-16 | 1.62B shares 10-Q · filed 2021-08-16 | |||||
| 2021-03-31 | 2.09M shares 10-Q · filed 2021-05-13 | |||||||
| 2020-12-31 | 3.37M shares 10-K · filed 2023-03-16 | |||||||
| 2020-09-30 | 3.31M shares 10-Q · filed 2020-11-12 | |||||||
| 2020-06-30 | 3.31B shares 10-Q · filed 2021-08-16 | 3.97B shares 10-Q · filed 2021-08-16 | 3.31M shares 10-Q · filed 2020-08-12 | |||||
| 2020-03-31 | 3.59M shares 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | 3.59M shares 10-K · filed 2022-03-16 | |||||||
| 2019-09-30 | 3.57M shares 10-Q · filed 2020-11-12 | |||||||
| 2019-06-30 | 3.46M shares 10-Q · filed 2020-08-12 | |||||||
| 2019-03-31 | 3.31M shares 10-Q · filed 2020-05-14 | |||||||
| 2018-12-31 | 8.26M shares 10-K · filed 2021-03-16 | |||||||
| 2018-09-30 | 9.04M shares 10-Q · filed 2019-11-14 | |||||||
| 2018-06-30 | 9.16M shares 10-Q · filed 2019-08-06 | |||||||
| 2018-03-31 | 9.17M shares 10-Q · filed 2019-05-07 | |||||||
| 2017-12-31 | 6.98M shares 10-K · filed 2020-03-05 | |||||||
| 2017-09-30 | 5.75M shares 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |